News

Gene therapy back on track
Enlarge image

BusinessNetherlands

Gene therapy back on track

23.07.2012 - A ray of hope for Dutch gene therapy specialist uniQure B.V.: EMA's CHMP
recommended approval of its product Glybera to treat lipoprotein lipase (LPL) deficiency in patients with severe or multiple pancreatitis attacks.

EMA said Glybera (alipogene tiparvovec) is the first gene therapy drug to receive a positive CHMP recommendation. The news is a relief for Amsterdam-based uniQure, after having received three negative opinions before. CHMP said it reversed its prior negative opinions following a draft positive opinion in June from the Committee for Advanced Therapies (CAT),which conducted additional analyses of the data for the adeno-associated virus (AAV) vector encoding LPL gene. CHMP said Glybera should be approved under EMA's exceptional circumstances clause, and that the company be required to establish a patient registry to monitor outcomes. uniQure expects a final decision from the European Commission within three months.

UniQure's predecessor, Amsterdam Molecular Therapeutics Holding N.V., first applied for European approval of the gene therapy in December 2009 for all patients with LPL deficiency. CHMP subsequently issued three negative opinions for Glybera, the most recent of which came in April following arequest by the EC to consider the product in a restricted patient population with severe or multiple pancreatitis attacks. Amsterdam Molecular dissolved into uniQure this February.

LPL disease is a very rare, inherited disease which affects 1-2 people per million. Patients with the disease are unable to handle fat particles in their blood plasma, which leads to recurring severe abdominal pain andpancreatitis. "After today's positive recommendation, Glybera is poised tobecome the first in a class of gene therapy products approved in Europe to treat orphan diseases, rare conditions with a very high unmet medical need", Jörn Aldag, CEO of uniQure, said.

http://www.european-biotechnology-news.com/news/news/2012-03/gene-therapy-back-on-track.html

BiofuelsEU

30.04.2015 The European Parliament has given the go-ahead on a new law limiting the use of harmful crop-based biofuel in the transport sector. The decision marks a breakthrough in the EU’s approach to biofuels.

FinancingSwitzerlandUK

29.04.2015 Biopharma start-up CRISPR Therapeutics has raised US$64m to hurry the new CRISPR/Cas9 technology to the clinic.

FinancingBelgium

28.04.2015 After having raised €100m in its stock market debut, MDx company Biocartis has gained 13 percent on its first trading day.

R&DFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • MEDIGENE10.96 EUR4.88%
  • EVOLVA1.58 CHF3.27%

FLOP

  • BIOTEST71.00 EUR-3.92%
  • SYNGENTA314.40 CHF-3.65%
  • 4SC5.03 EUR-3.27%

TOP

  • 4SC5.03 EUR293.0%
  • WILEX4.33 EUR51.4%
  • SARTORIUS151.00 EUR21.2%

FLOP

  • CYTOS1.01 CHF-29.4%
  • BIOTEST71.00 EUR-26.9%
  • BIOFRONTERA2.30 EUR-11.2%

TOP

  • SANTHERA96.45 CHF2329.5%
  • CYTOS1.01 CHF676.9%
  • WILEX4.33 EUR397.7%

FLOP

  • MOLOGEN4.94 EUR-55.4%
  • BIOFRONTERA2.30 EUR-29.2%
  • BIOTEST71.00 EUR-20.0%

No liability assumed, Date: 02.05.2015